HeartSine Technologies recalled over 1.2 million defibrillator pads on September 18, 2025. The recall affects several models due to defective pins that may disrupt electrical contact. Consumers and healthcare providers should stop using these pads immediately.
Due to customer complaints, defibrillator pads may contain damage pins that disrupt the mechanical fit and electrical contact.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact HeartSine Technologies Ltd or your healthcare provider for instructions. Notification method: Letter
The recall includes HeartSine Pad-Pak models: PAD-PAK-01, PAD-PAK-02, PAD-PAK-03, PAD-PAK-04, PAD-PAK-07, PAD-PAK-03J, and PAD-PAK-04J. A total of 1,291,165 units were distributed across the U.S. and internationally.
Defective pins in the recalled defibrillator pads may disrupt the mechanical fit and electrical contact. This defect poses a high risk to patients relying on these devices for emergency cardiac care.
There have been customer complaints regarding the malfunction, but no specific injury or death counts were reported.
Stop using the affected defibrillator pads immediately. Follow the recall instructions provided by HeartSine Technologies and contact your healthcare provider for further guidance.
For more information, contact HeartSine Technologies Ltd. Visit their website or refer to the FDA notice at https://www.accessdata.fda.gov/scripts/enforcement/enforce_rpt-Product-Tabs.cfm?recall_number=Z-0288-2026.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.